Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 19/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 18/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6607186 | 0.97 | SLC6A3 (0.39) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL2743225 | 0.92 | — | — | |
| SCHEMBL9944706 | 0.85 | — | — | |
| SCHEMBL2761898 | 0.77 | SLC6A4 (0.34) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL2761539 | 0.77 | SLC6A4 (0.34) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL27405489 | 0.75 | — | — | |
| SCHEMBL23570011 | 0.74 | — | — | |
| SCHEMBL13900941 | 0.74 | — | — | |
| SCHEMBL22944295 | 0.72 | PIK3CD (0.33) | — | |
| Hydrochloric Acid SCHEMBL30911735 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020020220-A1 | QUANTUM DOT-BASED LONG AFTERGLOW COMPOSITE MATERIAL, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF | TCL集团股份有限公司 | 2020-01-30 | — | — | WO | claimed |
| US-20210040089-A1 | KRAS MUTANT PROTEIN INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. | 2021-02-11 | — | — | US | disclosed |
| EP-1955697-B1 | 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | SLC6A3 1006/4885SLC6A4 431/4885SLC6A2 618/4885 |
| US-20210040089-A1 | KRAS MUTANT PROTEIN INHIBITORS | KRAS, NRAS, APC | SLC6A3 4804/4885SLC6A4 4870/4885SLC6A2 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.